Truncated HER2: implications for HER2-targeted therapeutics

@article{Zagozdzon2011TruncatedHI,
  title={Truncated HER2: implications for HER2-targeted therapeutics},
  author={Radoslaw Zagozdzon and William M. Gallagher and John Crown},
  journal={Drug discovery today},
  year={2011},
  volume={16 17-18},
  pages={
          810-6
        }
}
The HER2 receptor is currently one of the flagship therapeutic targets in clinical oncology. Trastuzumab, an antibody targeting HER2, has become a foundation of care in women with HER2-positive breast cancer. However, many women with metastatic breast cancer do not respond to trastuzumab-based therapy. One possible source of trastuzumab resistance is the presence of truncated forms of HER2 in the tumor. Numerous studies suggest that detection of truncated HER2 in the tumor should result in… CONTINUE READING
Highly Cited
This paper has 21 citations. REVIEW CITATIONS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Engineering inhibitory proteins with InSiPS: the in-silico protein synthesizer

SC15: International Conference for High Performance Computing, Networking, Storage and Analysis • 2015
View 1 Excerpt